Case Detail

Allergan, Inc. v. Alcon Laboratories, Inc.
On December 1, 2003, the U.S. Supreme Court declined to review an appeals court decision that denies a pharmaceutical company legal recourse when one of its patents is threatened by a generic drug company's announced plan to market a generic version of the drug covered by the patent. The decision was a setback for WLF, which filed a brief urging the Court to review the case. WLF argued that the decision below significantly undermines the financial incentives that the patent system normally provides to induce research and development of new, life-saving therapies. WLF also filed briefs in the case when it was in the appeals court.
Case Status:
Supreme Court review denied
More Information and Downloads:
10/24/2003: Download the Brief

  • Welcome to the Washington Legal Foundation
  • 2009 Massachusetts Ave., NW
    Washington, DC 20036
  • info@wlf.org  |  ph. 202-588-0302
    ©2018 WLF All Rights Reserved